Reading RLMD? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track RLMD free→Reading RLMD? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track RLMD free→QuarterlyIQ Insights · RLMD
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On May 12, 2026, Relmada Therapeutics, Inc. (the “Company”) issued a press release providing a corporate update and reporting its financial results for the three months ended March 31, 2026. The Company also announced that it would conduct a conference call and audio webcast on Tuesday, May 12, 2026, at 4:30 PM EST / 1:30 PM PST, to discuss the update and results. The Company’s complete unaudited condensed consolidated financial statements and no…
Results of Operations and Financial Condition. On March 19, 2026, Relmada Therapeutics, Inc. (the “Company”) issued a press release providing a corporate update and reporting its financial results for the fiscal year ended December 31, 2025. The Company also announced that it would conduct a conference call and audio webcast on Thursday, March 19, 2026, at 4:30 PM EST / 1:30 PM PST, to discuss the update and results. The Company’s complete audited financial statements and notes thereto as of,…
Unregistered Sales of Equity Securities. The disclosure regarding the securities to be sold and issued under the Purchase Agreement as set forth under
Regulation FD Disclosure. On March 9, 2026, the Company issued a press release announcing NDV-01 12-month Phase 2 data. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. Also on March 9, 2026, the Company issued a press release announcing the Private Placement. A copy of the press release is furnished as Exhibit 99.2 to this Current Report on Form 8-K. Also on March 9, 2026, the Company made available a presentation relating to NDV-01 12-month Phase…
Entry into a Material Definitive Agreement. On March 9, 2026, Relmada Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) for a private placement (the “Private Placement”) with certain institutional and accredited investors (each, a “Purchaser” and collectively, the “Purchasers”). The closing of the Private Placement (the “Closing”) is expected to occur on March 11, 2026, subject to the satisfaction of customary closing conditions. Pursua…
Other Events. On March 9, 2026, the Company announced 12-month interim data from its ongoing Phase 2 trial evaluating NDV-01 in patients with high-risk non-muscle invasive bladder cancer (“NMIBC”). The Phase 2 trial of NDV-01 demonstrated a 12-month complete response (“CR”) rate of 76% with a favorable safety profile. A 12-month CR rate of 80% was achieved in the Bacillus Calmette-Guérin (“BCG”)-unresponsive population, one of the most difficult-to-treat segments of NMIBC. Taken together, the…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 12, 2025, the Board of Directors the Board of Directors of Relmada Therapeutics, Inc. (the “Company”) approved an amended and restated employment agreement with each of its executive officers, each to become effective as of January 1, 2026. Except as described below, the material terms of each executive officer’s employment agreement, a…
Results of Operations and Financial Condition. On November 13, 2025, Relmada Therapeutics, Inc. (the “Company”) issued a press release providing a corporate update and reporting its financial results for the third fiscal quarter ended September 30, 2025. (These results are preliminary and unaudited.) The Company also announced that it would conduct a conference call and audio webcast on Thursday, November 13, 2025, at 4:30 PM EST / 1:30 PM PST, to discuss the update and results. The Company’s…
Entry into a Material Definitive Agreement. On November 4, 2025, Relmada Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC and Leerink Partners LLC, as representatives of the several underwriters named therein (collectively, the “Underwriters”), in connection with an underwritten offering (the “Offering”) of (i) 40,142,000 shares (“Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”),…
Regulation FD Disclosure. On November 4, 2025, 2025, the Company issued a press release announcing that it had priced the Offering. A copy of the press release is furnished hereto as Exhibit 99.1 to this Current Report on Form 8-K. Statements contained in this Current Report on Form 8-K regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may involve risks and uncertainties,…
Other Events. FDA Feedback on proposed NDV-01 Phase III Trials The FDA indicated that in the Bacillus Calmette-Guerin (BCG)-unresponsive setting, a single arm trial may be acceptable in a patient population refractory to other therapies, with the details of such a design to be discussed further with the FDA. The FDA also indicated that, a randomized, post-transurethral resection of the bladder tumor (“TURBT”) adjuvant study comparing NDV-01 to observation in intermediate risk non-muscle invas…
Results of Operations and Financial Condition. On August 7, 2025, Relmada Therapeutics, Inc. (the “Company”) issued a press release providing a corporate update and reporting its financial results for the second fiscal quarter ended June 30, 2025. (These results are preliminary and unaudited.) The Company also announced that it would conduct a conference call and audio webcast on Thursday, August 7, 2025, at 4:30 PM EDT / 1:30 PM PDT, to discuss the update and results. The Company’s complete…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed, on January 21, 2025, Relmada Therapeutics, Inc. (the “Company”) received a written notification from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the 30 consecutive business days ended January 17, 2025, the Company’s security did not maintain a minimum bid price of $1 per share. Nasdaq stated in its letter…
Termination of a Material Definitive Agreement. In January 2018, Relmada Therapeutics, Inc. (“Relmada,” the “Company,” “we,” “us,” “our”) entered into a License Agreement (the “License Agreement”) with Dr. Charles E. Inturrisi and Dr. Paolo Manfredi (collectively, the Licensor). Pursuant to the License Agreement, Licensor granted Relmada a perpetual, worldwide, and exclusive license to commercialize Licensor’s rights, including patents and patent applications, to esmethadone in the context of…
Changes in Registrant’s Certifying Accountant. (a) Resignation of Independent Registered Public Accounting Firm On November 1, 2024, CBIZ CPAs P.C. (“CBIZ CPAs”) acquired the attest business of Marcum LLP (“Marcum”). On May 8, 2025, the Company dismissed Marcum as the Company’s independent registered public accounting firm as a result of such acquisition, and the Company’s audit committee approved the dismissal. The audit report of Marcum on the Company’s consolidated financial statements as…
Results of Operations and Financial Condition. On March 27, 2025, Relmada Therapeutics, Inc. (the “Company”) issued a press release providing a corporate update and reporting its financial results for the fourth quarter and full year ended December 31, 2024. (These results are preliminary and unaudited.) The Company also announced that it would conduct a conference call and audio webcast on Thursday, March 27, 2025, at 4:30 PM EDT / 1:30 PM PDT, to discuss the update and results. The Company’…
Entry into a Material Definitive Agreement. License Agreement On March 24, 2025, Relmada Therapeutics, Inc., a Nevada corporation (“Relmada,” the “Company, “we, “us,” “our”) entered into a Exclusive License Agreement (the “License Agreement”) with Trigone Pharma, Ltd., an Israeli company (“Trigone”) pursuant to which we will obtain (a) an exclusive, royalty-bearing, non-transferable license under the licensed patents and know-how of Trigone and related technical information (the “Licensed IP”…
Unregistered Sales of Equity Securities. The information set forth in
Entry into a Material Definitive Agreement. On February 3, 2025, Relmada Therapeutics, Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Asarina Pharma AB (“Asarina” or the “Seller”), a Swedish corporation, pursuant to which the Company has agreed, subject to the terms and conditions set forth therein, to purchase from Asarina all right, title, and interest in Sepranolone (the “Asset”), a phase 2b ready neurosteroid being developed for the treatment…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On January 21, 2025, Relmada Therapeutics, Inc. (the “Company”) received a written notification from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the 30 consecutive business days ended January 17, 2025, the Company’s security did not maintain a minimum bid price of $1 per share. Nasdaq stated in its letter that in accordance with N…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.